Breaking News

Triphase Accelerator Initiates Phase I Trial of TRPH-222

Next-Gen Antibody-Drug Conjugate developed using Catalent’s SMARTag ADC Technology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Triphase Accelerator, a company dedicated to acquiring and developing cancer therapeutics, initiated a Phase I trial of TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma. TRPH-222 was originally developed by Catalent’s subsidiary Redwood Bioscience, Inc. using the  SMARTag platform, which provides optimized site-specific protein-modification and linker technologies. Triphase Accelerator obtained worldwide rights to further develop this program and s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters